Exicure, Inc. Reports Full Year 2025 Financial Results
Exicure, Inc. disclosed its full-year 2025 financial results, reporting a net loss of $4.9 million, an improvement from $9.7 million in 2024 primarily due to a $6 million gain from early lease termination. The company incurred increased R&D and administrative expenses following its acquisition of GPCR Therapeutics USA Inc. It ended 2025 with $3.7 m…